Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing
cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients
diagnosed with schizophrenia.